RecruitingAtrial FibrillationStrokeBleeding

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Eligible age

18+ yrs

Accepts

All genders

Locations

27 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

Sponsor: Icahn School of Medicine at Mount Sinai

You may qualify if…

✓ Patients of age ≥18 years who undergo isolated CABG for coronary artery disease
✓ POAF that persists for \>60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery

You may not qualify if…

✕ Clinical history of either permanent, persistent or paroxysmal atrial fibrillation
✕ Any pre-existing clinical indication for long-term OAC
✕ Any absolute contraindication to OAC
✕ Planned use of post-operative dual antiplatelet therapy (DAPT)
✕ a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent.
✕ Cardiogenic shock
✕ Major perioperative complication\* occurring between CABG and randomization
✕ a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade).